Eli Lilly and Novo Nordisk, two major pharmaceutical companies, have reached an agreement with the Trump administration to lower the prices of their obesity drugs, Zepbound and Wegovy. This deal will provide tariff relief and wider Medicare access for these drugs in exchange for the price reductions. The article highlights that these obesity medications are considered "blockbuster" drugs, meaning they are highly successful and profitable for the companies. The price cuts are seen as a significant move, as the high costs of these drugs have been a barrier for many patients seeking treatment for obesity. The agreement aims to improve affordability and accessibility of these crucial weight-loss drugs, which can have a significant impact on the health and well-being of individuals struggling with obesity. The article suggests that this deal is part of the Trump administration's efforts to address the rising costs of healthcare and make essential medications more accessible to the public.
Nov 6, 2025 → Nov 26, 2025
The U.S. government has announced negotiated prices for 15 drugs under Medicare, the federal health insurance program for the elderly and disabled. The new prices are expected to result in significant savings for the program. According to…
Read original at NYT →3 updates from 2 sources over 3 weeks.
The U.S. government has announced negotiated prices for 15 drugs under Medicare, the federal health insurance program for the elderly and disabled. The new prices are expected to result in significant savings for the…
Read original at NYT →President Trump announced a deal with pharmaceutical companies Eli Lilly and Novo Nordisk to lower the prices of obesity drugs for Medicare, Medicaid, and self-paying patients. The deal aims to make these weight-loss…
Read original at NYT →Eli Lilly and Novo Nordisk, two major pharmaceutical companies, have reached an agreement with the Trump administration to lower the prices of their obesity drugs, Zepbound and Wegovy. This deal will provide tariff…
Read original at Bloomberg →What this story stands on. Tier 0 is a primary record or the subject's own words; higher tiers must be attributed, never stated as bare fact.
The U.S. government has announced negotiated prices for 15 drugs under Medicare, the federal health insurance program for the elderly and disabled. The new prices are expected to result in significant savings for the program. According to…
View source →President Trump announced a deal with pharmaceutical companies Eli Lilly and Novo Nordisk to lower the prices of obesity drugs for Medicare, Medicaid, and self-paying patients. The deal aims to make these weight-loss medications more…
View source →Eli Lilly and Novo Nordisk, two major pharmaceutical companies, have reached an agreement with the Trump administration to lower the prices of their obesity drugs, Zepbound and Wegovy. This deal will provide tariff relief and wider…
View source →Tier key: T0 = Primary source · T1 = Wire · T2 = Outlet report · T3 = Commentary
Long-running fight over Trump-backed maps takes another turn as absentee voting is already under way in Missouri. This blog is now closed. Sign up for US Breaking News emails Xi…
This new task force is Trump's latest response to the debate over AI safety.
The Trump administration’s decision to revoke the visa of a Peruvian judge who sided with a Chinese company in a port dispute puts a new spotlight on the growing US-China rivalry…
As Bosnians vote in an election this weekend, the country is embracing the US president’s family and friends.
On Equity, we discussed the Trump administration's attempts to rebrand AI.
Donald Trump and Xi Jinping discuss Taiwan arms sales every time they get together but the American stance on the self-ruled island remains unchanged following the Chinese…
